Skip to main content

Isogen to Distribute Axela Platforms

NEW YORK (GenomeWeb News) – Isogen Life Science will distribute Axela's multiplex biomarker platforms in Benelux and Spain under an agreement announced by the firms today.

Isogen, based in De Meern, The Netherlands, will manage sales and support of Axela's flow through systems to clinical research markets in the designated countries. Platforms covered by the deal include Axela's Ziplex Research System for gene and protein microarray analysis, the dotLab mX System for real-time multiplex immunoassays, and the panelPlus technology for creating custom multiplex panels for biomarker analysis.

Financial and other terms of the alliance were not disclosed.

"The Ziplex and dotLab mX product range nicely complement our portfolio of distributed and internally developed products for life science research markets," Isogen Managing Director Hans Beijersbergen van Henegouwen said in a statement. "Working closely with the Axela team, we will be able to provide our customers with robust, time-saving solutions for their biomarker discovery and validation projects."

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.